-
Mashup Score: 4EC Approves Frontline Tislelizumab Plus Chemo for Advanced ESCC and Gastric/GEJ Cancer - 7 hour(s) ago
Tislelizumab plus chemotherapy has been approved in Europe for first-line advanced ESCC and gastric/GEJ adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer - 5 day(s) ago
Zolbetuximab plus chemotherapy extended PFS and OS in HER2–, locally advanced unresectable or metastatic, CLDN18.2+ gastric/GEJ adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer #esocsm #oncology https://t.co/p0m8QHwb3a
-
-
Mashup Score: 1Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer - 8 day(s) ago
Zolbetuximab plus chemotherapy extended PFS and OS in HER2–, locally advanced unresectable or metastatic, CLDN18.2+ gastric/GEJ adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer #esocsm #oncology https://t.co/p0m8QHwb3a
-
-
Mashup Score: 0Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer - 15 day(s) ago
Zolbetuximab plus chemotherapy extended PFS and OS in HER2–, locally advanced unresectable or metastatic, CLDN18.2+ gastric/GEJ adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer #esocsm #oncology https://t.co/p0m8QHwb3a
-
-
Mashup Score: 4Frontline Tislelizumab/Chemo Approaches EU Approval for Gastric/GEJ Adenocarcinoma and ESCC - 1 month(s) ago
The European Medicines Agency has recommended extended authorization for frontline tislelizumab plus chemotherapy for GEJ adenocarcinoma and ESCC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Frontline Tislelizumab/Chemo Approaches EU Approval for Gastric/GEJ Adenocarcinoma and ESCC @FlorianLordick #esocsm #oncology https://t.co/Jr5SvqbcPj
-
-
Mashup Score: 6Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer - 4 month(s) ago
Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer @myesmo #esocsm #oncology https://t.co/Y3VGwfgNJS
-
-
Mashup Score: 6Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer - 4 month(s) ago
Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer @myesmo #esocsm #oncology https://t.co/Y3VGwfgNJS
-
-
Mashup Score: 6Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer - 5 month(s) ago
Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer @myesmo #esocsm #oncology https://t.co/Y3VGwfgNJS
-
-
Mashup Score: 0FDA Grants Orphan Drug Designation to 9MW2821 for Esophageal Cancer - 7 month(s) ago
The FDA has granted orphan drug designation to 9MW2821 as a potential treatment for patients with esophageal cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
The FDA has granted orphan drug designation to 9MW2821 as a potential treatment for patients with esophageal cancer. @us_fda #esocsm #oncology https://t.co/kzjCf4pIfg https://t.co/siGXE9Xfud
-
-
Mashup Score: 15
The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
BREAKING: @US_FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy #esocsm #oncology https://t.co/CHlrBg83mJ https://t.co/SzzaIsXw2G
-
EC Approves Frontline Tislelizumab Plus Chemo for Advanced ESCC and Gastric/GEJ Cancer @FlorianLordick @UniLeipzig #esocsm #oncology https://t.co/r9Svxc1Zw2